Outlook Therapeutics(OTLK) - 2025 Q2 - Quarterly Results

Financial Performance - For the fiscal second quarter ended March 31, 2025, Outlook Therapeutics reported a net loss of $46.4 million, or$1.50 per share, compared to a net loss of $114.3 million, or$8.01 per share, for the same period last year[11]. - The adjusted net loss for the fiscal second quarter was $12.5 million, or$0.40 per share, down from an adjusted net loss of $22.1 million, or$1.55 per share, in the fiscal second quarter of 2024[11]. - For the three months ended March 31, 2025, the net loss attributable to common stockholders was $46.358 million, compared to a net loss of$114.289 million for the same period in 2024, representing a 59.3% improvement[26]. - The adjusted net loss attributable to common stockholders (non-GAAP) for the three months ended March 31, 2025, was $12.450 million, compared to$22.057 million in 2024, a reduction of 43.5%[26]. - The company reported a loss from operations of $12.391 million for the three months ended March 31, 2025, compared to a loss of$18.940 million in the same period of 2024, a 34.5% decrease[26]. - The loss before income taxes for the six months ended March 31, 2025, was $28.977 million, a significant improvement from$125.464 million in the same period of 2024, representing a 77.0% reduction[26]. Cash and Assets - As of March 31, 2025, Outlook Therapeutics had cash and cash equivalents of $7.6 million[13]. - Cash and cash equivalents decreased to$7.556 million as of March 31, 2025, from $14.928 million in 2024, a decline of 49.3$19.075 million as of March 31, 2025, from $28.823 million in 2024, a decline of 33.7$32.463 million as of March 31, 2025, from $73.077 million in 2024, reflecting a 55.6$14.067 million, down from $18.038 million in the same period of 2024, indicating a 22.0$33.857 million for the three months ended March 31, 2025, compared to no such expenses in the same period of 2024[26].